PVIVAX

Knowledge sharing for relapsing malaria

Search

  • P. vivax malaria
    • Malaria and P. vivax malaria
    • Symptoms & severity
    • Illness and mortality
    • Populations at risk
      • Pregnant women and children
      • Migratory populations
    • Role in malaria elimination
    • Lifecycle
    • Relapses
    • Vectors
  • Diagnosis & treatment
    • Diagnostic methods
      • Microscopy
      • Rapid diagnostic tests
      • Molecular methods & serology
    • Diagnosing severe vivax malaria
    • Treatment
      • Radical cure
      • Blood stage treatment
      • Liver stage treatment
    • G6PD Deficiency
      • G6PD Global Prevalence
      • G6PD diagnostics
      • Types of G6PD clinical diagnostic tests
  • Regions & countries
    • Africa
    • Eastern Mediterranean
    • South East Asia
    • The Americas
    • Western Pacific
  • In the field
    • Projects
    • Stories and Videos
  • Tools
    • Study database
  • Resources
  • News & events
  • About us
Map with highlighted countries to indicate where studies are taking place

P. vivax malaria studies:  A database of studies focusing on improving access to radical cure.

View the database

Flyer for the event
Photo: istock

About the P. vivax information hub 

Find out more
Photo: istock
Photo: Schumann/MMV

Video on life-changing treatment to cure relapsing P. vivax malaria.

Photo: Schumann/MMV

Featured resources

Screenshot of video
06 Aug 2021

From pipeline to policy to optimized implementation: Next steps for the APMEN VxWG

This short video outlines the APMEN Vivax Working Group's workplan for 2021 - 2022.

MMV
Videos
top corner of document zoomed in
05 Aug 2021

New treatment for P. vivax malaria may benefit Brazilian public health

This briefing provides an overview of the population-level transmission dynamics modelling study by Nekkab et al. on the estimated impact of tafenoquine (TQ) on control and elimination of P. vivax malaria in Brazil. The briefing is available in English, Spanish and Portuguese. 

Partnership for Vivax Elimination (PAVE)
Fact sheet
Healthworker and patient in a consultation

Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research

PAVE is conducting feasibility studies and operational research to support Ministries of Health in malaria endemic countries to look at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the healthcare system in support of their elimination goals.
Patient and health worker in consultation

the Tafenoquine Roll-oUt STudy (TRuST)

The Brazilian Ministry of Health (MoH) and MMV, are conducting a study to understand the feasibility of providing appropriate radical cure treatment (primaquine - PQ - or tafenoquine – TQ) based on the results of G6PD testing conducted in real-world settings. 
1

News

quote and photo of person quoted

P. vivax radical cure in Latin America: regional coordination to advance malaria elimination

17 Dec 2021
microbiology laboratory in Porto Velho, Brazil

First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration

08 Oct 2021
quote and photo of people quoted

New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

14 Jul 2021
Gloved hands performing STANDARD G6PD test

STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration

25 May 2021
View news and events
1

Events

Flyer for the event
05
Apr
2022

8th International Conference on Plasmodium vivax Research (ICPvR) 2022

The 8th International Conference on Plasmodium vivax Research will take place virtually from 5th - 8th April 2022. Deadline for abstract submissions: 12th January 2022.

5th - 8th April 2022
Global virtual event
1

Publications

Available online 3 December 2021

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and evaluated tafenoquine efficacy and safety in children infected with P. vivax.

Lancet Child & Adolescent Health
Peer-reviewed article
30 Oct 2021

Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria

This study aimed to map out the national antimalarial policy processes in seven endemic countries to identify areas where it can be improved to align with best practices and optimal efficiency.

Malaria Journal
Peer-reviewed article
08 Oct 2021

Eliminating malaria in southeast Asia requires more attention on adolescent girls

Malaria is one of the leading causes of death among adolescent girls in southeast Asia. Young adolescent girls (aged 10–14 years), for whom malaria is the eighth highest cause of mortality, are most affected. On the basis of the most recent data (which is for the year 2016), the malaria mortality rate for young adolescent girls in southeast Asia is 28% higher than for young adolescent boys (1·75 deaths vs 1·37 deaths [per 100 000 of the population at risk]).

Lancet Child Adolescent Health
Peer-reviewed article
25 Sep 2021

Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial

There is a high risk of Plasmodium vivax recurrence in patients treated for Plasmodium falciparum malaria in co-endemic areas. Primaquine radical cure has the potential to reduce P. vivax recurrences in patients presenting with P. falciparum as well as P. vivax malaria but is undermined by poor adherence to the currently recommended 14-day regimen. We aimed to assess the efficacy and safety of supervised versus unsupervised primaquine radical cure in patients presenting with uncomplicated malaria.

The Lancet Infectious Diseases
Peer-reviewed article
View all publications

Get in touch

Contact us.

Submit information

Subscribe

Follow us

  • Twitter
  • LinkedIn
  • Facebook
  • Disclaimer
  • Privacy policy
A Remora website by Manta Ray Media